Succeeding in Specialty Management

[S2] A Whole New World: Navigating the Gene Therapy Pipeline

ACPE UAN: 0233-0000-18-020-L04-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

• 

  Nicole Trask, PharmD

  Clinical Consultant Pharmacist
  University of Massachusetts Clinical Pharmacy Services
  Shrewsbury, Massachusetts

Moderator(s)

• BG

  Bonnie Greenwood, PharmD, BCPS

  Clinical Program Director
  UMass Medical School, Clinical Pharmacy Services
  Shrewsbury, Massachusetts

Gene therapy promises to make waves — both clinically and financially — as it crashes onto the market. Gene therapies in development for human immunodeficiency virus (HIV), spinal muscular atrophy (SMA), hemophilia, and sickle cell anemia promise to transform the way we manage these devastating disease states. While they may provide cures that were once only dreamed of, gene therapies also represent staggering costs. These costs leave payers wondering how they will afford to deliver these therapies to the patients who need them most.

After this presentation, participants will be better prepared to anticipate the budget impact of gene therapy on their program and develop strategies for the management of these high-cost agents.

Learning Objectives:

At the completion of this activity, participants should be able to:

1. Define gene therapy and discuss therapeutic indications being targeted for gene therapy.
2. Identify gene therapies currently in late-stage development.
3. Summarize the clinical data for gene therapies within the pharmaceutical pipeline.
4. Discuss resources available for research and evaluation of gene therapies as well as lessons learned past experiences in this field.